0000000000305903

AUTHOR

Lucía Llanos

showing 3 related works from this author

Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

2019

The Collaborative Working Group “Noma Project Team”.

0301 basic medicinelcsh:Immunologic diseases. Allergycritical limb ischemiaCell typecost-effectivecell-based therapyImmunologyBioinformaticsCell therapy03 medical and health sciences0302 clinical medicineImmunology and AllergyMedicineOriginal Researchclinical trialsdiabetesbusiness.industryMesenchymal stem cellType 2 Diabetes MellitusCritical limb ischemiacellular medicamentsClinical trial030104 developmental biologyStem cellmedicine.symptombusinesslcsh:RC581-607030215 immunologyAdult stem cell
researchProduct

Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis.

2008

We tested the hypothesis that the presence of bacterial DNA (bactDNA) in ascitic fluid and serum is associated with decreased survival in patients with cirrhosis. In a prospective, multicenter study, we analyzed the clinical evolution of 156 patients with cirrhosis and ascites (first or recurrence) with lower than 250 polymorphonuclear cells (PMN)/L, negative ascites bacteriological culture, and absence of other bacterial infections being admitted for evaluation of largevolume paracentesis, according to the presence of bactDNA at admission. Survival, causes of death, and successive hospital admissions were determined during a 12-month follow-up period. BactDNA was detected in 48 patients. T…

AdultDNA BacterialLiver CirrhosisMalemedicine.medical_specialtyCirrhosisNeutrophilsKaplan-Meier EstimatePeritonitisGastroenterologyLiver diseaseSpontaneous bacterial peritonitisRisk FactorsInternal medicineAscitesParacentesisEscherichia coliMedicineAscitic FluidHumansProspective StudiesProspective cohort studyCause of deathAgedAged 80 and overHepatologymedicine.diagnostic_testbusiness.industryIncidenceAscitesHepatologyMiddle Agedmedicine.diseasePrognosisSurgeryMultivariate AnalysisFemalemedicine.symptombusinessLiver FailureFollow-Up StudiesHepatology (Baltimore, Md.)
researchProduct

Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus.

2020

[This corrects the article DOI: 10.3389/fimmu.2019.01151.].

lcsh:Immunologic diseases. Allergycritical limb ischemiamedicine.medical_specialtyclinical trialsdiabetesbusiness.industrycost-effectivecell-based therapyImmunologyType 2 Diabetes MellitusCorrectionCritical limb ischemiamedicine.diseasecellular medicamentsCell therapyClinical trialDiabetes mellitusInternal medicinemedicineImmunology and Allergymedicine.symptombusinesslcsh:RC581-607
researchProduct